Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stryker investors not fazed by spinal device recall

This article was originally published in Clinica

Executive Summary

Stryker has been slapped with a Class I recall from the US FDA for a component of its OASYS occipito-cervico-thoracic system, designed to aid spinal fusion. But the firm’s share price barely seemed to be affected, closing flat at $66.91 on 29 August, the day the FDA posted news of the recall on its website.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts